<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10076798</article-id><article-id pub-id-type="pmcid-ver">PMC10076798.1</article-id><article-id pub-id-type="pmcaid">10076798</article-id><article-id pub-id-type="pmcaiid">10076798</article-id><article-id pub-id-type="pmid">37033605</article-id><article-id pub-id-type="doi">10.3389/fphar.2023.1105176</article-id><article-id pub-id-type="publisher-id">1105176</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers</article-title><alt-title alt-title-type="left-running-head">Khani et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2023.1105176" ext-link-type="uri">10.3389/fphar.2023.1105176</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Khani</surname><given-names initials="S">Samira</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2109918/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tafaroji</surname><given-names initials="J">Javad</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2114781/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yaghoubi</surname><given-names initials="M">Mehdi</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/805246/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Emami Kazemabad</surname><given-names initials="MJ">Mohammad Javad</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1830091/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hejazi</surname><given-names initials="SA">Seyed Amir</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2249235/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Neuroscience Research Center</institution>, <institution>Qom University of Medical Sciences</institution>, <addr-line>Qom</addr-line>, <country>Iran</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Pediatric Medicine Research Center</institution>, <institution>Qom University of Medical Sciences</institution>, <addr-line>Qom</addr-line>, <country>Iran</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Cellular and Molecular Research Center</institution>, <institution>Qom University of Medical Sciences</institution>, <addr-line>Qom</addr-line>, <country>Iran</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Student Research Committee</institution>, <institution>School of Medicine</institution>, <institution>Qom University of Medical Sciences</institution>, <addr-line>Qom</addr-line>, <country>Iran</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1428670/overview" ext-link-type="uri">Grigorios L. Kyriakopoulos</ext-link>, National Technical University of Athens, Greece</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2167855/overview" ext-link-type="uri">Gelareh Vahabzadeh</ext-link>, Iran University of Medical Sciences, Iran</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/430074/overview" ext-link-type="uri">Daniela Calina</ext-link>, University of Medicine and Pharmacy of Craiova, Romania</p></fn><corresp id="c001">*Correspondence: Seyed Amir Hejazi, <email>assh.hejazi@gmail.com</email></corresp><fn fn-type="other"><p>This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427358</issue-id><elocation-id>1105176</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>07</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-11 05:10:23.263"><day>11</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Khani, Tafaroji, Yaghoubi, Emami Kazemabad and Hejazi.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Khani, Tafaroji, Yaghoubi, Emami Kazemabad and Hejazi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-14-1105176.pdf"/><abstract><p>
<bold>Background:</bold> Coronavirus disease (COVID-19) is a mild to severe infectious respiratory illness caused by the SARS-CoV-2 virus. Based on the numerous pieces of evidence regarding the role of opioids in immune function, viral replication, and virus-mediated pathology, we decided to assess the incidence and severity of COVID-19 outcomes in people undergoing opioid maintenance treatment.</p><p>
<bold>Methods:</bold> This is a prospective, descriptive, multi-center study that included 452 patients undergoing maintenance treatment in opioid agonist treatment (OAT) clinics in different cities of Iran. Demographic information, underlying disease, history of maintenance treatment, type of drug used, history of addiction, smoking, and the kind of substance abused, were recorded. A physician evaluated the COVID-19 symptoms, and the severity of the disease was defined based on the number of observed symptoms.</p><p>
<bold>Results:</bold> The results have not shown any significant difference in the severity of COVID-19 symptoms in different nationalities, gender, and treatment groups. Furthermore, the history of drug abuse, including time and type of abuse and smoking, has not indicated any significant association with the occurrence of symptoms. Only the severity of COVID-19 in the mentioned cities (first and second follow-up: <italic toggle="yes">p</italic> &lt; 0.001) and individuals with a history of underlying disease (first follow-up: <italic toggle="yes">p</italic> = 0.020; second follow-up: <italic toggle="yes">p</italic> = 0.043) were significantly different.</p><p>
<bold>Conclusion:</bold> Our results have demonstrated that the severity of symptoms in people with the underlying disease was significantly higher than in others. But there is no association between sex, race, treatment groups, and abuse history with the severity of COVID-19 symptoms in methadone maintenance treatment (MMT) patients.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>opioid</kwd><kwd>immunodulation</kwd><kwd>opioid agonist</kwd><kwd>methadone maintenance program</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Opioids are endogenous peptides (&#946;-endorphin, encephalin, and met-encephalin) or exogenous substances (e.g., morphine, methadone, etc.) that act through activating opioid receptors known as &#181;, &#954;, and <italic toggle="yes">&#948;</italic> (<xref rid="B9" ref-type="bibr">Feng et al., 2012</xref>). Opioid receptors are G protein-linked receptors located in the nervous system, kidney, spleen, liver, intestine, and lung. Also, opioid receptors are distributed in the immune cells such as lymphocytes, macrophages, neutrophils, and monocytes (<xref rid="B34" ref-type="bibr">Wang, 2019</xref>). Recent studies have shown that opioids have immunomodulatory and anti-inflammatory effects by influencing immune cell function. Effects of opioids on immune functions include downregulation of natural killer cells and T cell activities, depression of phagocytic activity of neutrophils and macrophages; affecting cytokine receptor expression (<xref rid="B10" ref-type="bibr">Finley et al., 2008</xref>), diminishing the formation of antibodies, cytokines, and other inflammatory mediators (<xref rid="B7" ref-type="bibr">Eisenstein, 2019</xref>).</p><p>The alkaloid of morphinane in opioids, through lysosomotropic properties, inhibits viral uncoating and the entrance of coronavirus (<xref rid="B4" ref-type="bibr">Cismaru et al., 2021</xref>). Moreover, opioids are effective in palliating dyspnea and limiting hyperventilation by decreasing respiratory drive and corollary discharge, altering the activity of lung opioid receptors, and having anxiolytic effects (<xref rid="B22" ref-type="bibr">Mahler, 2013</xref>).</p><p>COVID-19 is an atypical respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Dysregulated inflammatory response due to hypercytokinemia, has a pivotal role in severe COVID-19. Lymphopenia, lymphocyte dysfunction, granulocyte and monocyte abnormalities, high cytokine levels, and increased total antibodies are present in COVID-19 patients (<xref rid="B36" ref-type="bibr">Yang et al., 2020</xref>).</p><p>Two major pathways of COVID-19 transmission to people are respiratory droplets and face-to-face contact. 14&#160;days is regarded as a typical incubation period for COVID-19 (<xref rid="B26" ref-type="bibr">Rezaee et al., 2021</xref>). The real-time reverse-transcriptase-polymerase chain reduction (RT-PCR) method is used for the purpose of the COVID-19 final diagnosis (<xref rid="B5" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B28" ref-type="bibr">Rubin et al., 2020</xref>). Headache, loss of taste or smell, diarrhea, nausea, fatigue, etc., are some of the most common manifestations of this infectious disease (<xref rid="B3" ref-type="bibr">Chen et al., 2020</xref>; <xref rid="B14" ref-type="bibr">Huang et al., 2020</xref>; <xref rid="B18" ref-type="bibr">Lechien et al., 2020</xref>). It is reported that compared with the severe acute respiratory syndrome (SARS) coronavirus, COVID-19 has a higher level of infectivity but a lower mortality rate (<xref rid="B18" ref-type="bibr">Lechien et al., 2020</xref>). It seems that the mortality rate can be increased due to underlying disorders like diabetes and cancer (<xref rid="B25" ref-type="bibr">Nouri-Vaskeh et al., 2021</xref>).</p><p>Coronavirus is known to have four primary structural proteins: nucleocapsid proteins, envelope, membrane, and spike. The spike helps the coronavirus to enter the host cell (<xref rid="B19" ref-type="bibr">Li et al., 2003</xref>; <xref rid="B15" ref-type="bibr">Jia et al., 2005</xref>; <xref rid="B13" ref-type="bibr">Grass and Toole, 2015</xref>). After the first exposure, cytotoxic cells, antibodies, and interferons trigger the immune system. Alveolar infiltration of T cells, macrophages, and neutrophils occurs in the advanced levels of the disease (<xref rid="B16" ref-type="bibr">Khadke et al., 2020</xref>).</p><p>While attempting to provide therapies for patients with COVID-19, many treatments have been tested which often resulted in controversial consequences (<xref rid="B30" ref-type="bibr">Senefeld et al., 2023</xref>).</p><p>Some studies have indicated that opioid receptors have immunomodulatory effects. Therefore, it seems that opioid drugs can be effective not only in the viral infectious cycle, but also in the host&#8217;s reactions to COVID-19 by treating dyspnea, inhibiting the cytokine storm, and disrupting lysosomal acidification.</p><p>The type of virus determines the effects of the opioid system on human viral infections. The opioid system may enhance or suppress viral pathogenesis by altering host immune responses (<xref rid="B35" ref-type="bibr">Wang X. et al., 2005</xref>). The results of studies so far have shown that the opioid system accelerates HCV and HIV pathogenesis. On the contrary, it has a beneficial role in the outcome of respiratory viral diseases such as influenza virus and respiratory syncytial virus and could serve as effective therapeutic targets (<xref rid="B31" ref-type="bibr">Tahamtan et al., 2016</xref>).</p><p>Despite the use of these medications in the clinic, their role in the consequences of viral respiratory diseases has not yet been studied in detail. Due to the lack of studies related to the effectiveness of opioids in patients with COVID-19, we attempted to collect and provide some helpful information about the possible protective effects of this category of medications by evaluating patients referred to methadone maintenance treatment centers and following them up in terms of incidence, severity, and incidence of symptoms.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><p>This is a prospective, descriptive, multi-center study that included 452 patients undergoing maintenance treatment in opioid agonist treatment (OAT) clinics in Tehran, Qom, Khorasan, Esfahan, and Kashan cities of Iran. The study protocols were approved by the ethics committee of Qom University of Medical Sciences, Qom, Iran (particular approval ID: IR.MUQ. -REC.1394.73).</p><p>Sampling was performed through the Census method. All the patients eligible for the study (452 patients) with observance of the principles of confidentiality, honesty, the confidentiality of information, etc., were entered into the study from 1 April 2017, to 20 March 2018, and followed until 11 September 2020. Demographic information (age, gender, and body mass index), underlying diseases (diabetes, hypertension, heart failure, and chronic kidney disease), history of maintenance treatments, type of drugs used, history of addiction, smoking, and the kind of substance abused, were extracted from patient statements and files.</p><p>During the study period, patients were evaluated for COVID-related symptoms by a physician. Based on a checklist, including cough, fever, myalgia, headache, dyspnea, diarrhea, and loss of taste or smell, all the symptoms were recorded. The severity of the disease was defined based on the number of symptoms observed in the patient as follows: None: No symptoms; Mild: One to two symptoms; Moderate: Three symptoms; Severe: &#8805;4 symptoms. Finally, the severity of the disease was evaluated in the mentioned period. We analyzed collected data every 3&#160;months and presented it as the first follow-up: the first trimester of study; second follow-up: the second trimester of study, in this group of patients. Furthermore, the hospitalization rate and mortality were recorded during the study (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Flow diagram of participants through the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1105176-g001.jpg"/></fig></sec><sec id="s3"><title>Statistical analysis</title><p>The SPSS statistical software version 25.0 (SPSS Inc., Chicago, IL, United States of America) was used for data analysis. Age, BMI, history of drug abuse, and MMT history (year), were expressed as the mean &#177; SD and were compared using ONEWAY ANOVA, <italic toggle="yes">post hoc</italic> Tukey test. The remaining parameters (e.g., gender, nationality, etc.), were presented as n (%), and the comparisons between different severity groups were examined by the Chi-square test. P-value &lt;0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="s4"><title>Results</title><p>During the study period, 452 patients were enrolled in this research. The median age was 44.92 &#177; 12.06 years, and 426 (94.3%) were men. <xref rid="T1" ref-type="table">Table 1</xref> shows the demographic characteristics of those who entered the study. The underlying disease and medication history of patients have summarized in <xref rid="T2" ref-type="table">Table 2</xref>. 77.4% of patients had not any underlying disease. Heart disease (6.6%) and hypertension (10.6%) were more common among patients. 93.8% of patients had a history of drug abuse for more than 1&#160;year, and opium addiction is more common (82.3%) in these patients. 75.2% of patients have used methadone as maintenance therapy.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic information of patients referred to MMT centers. (n = 452).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Parameters</th><th align="right" rowspan="1" colspan="1">(n = 452)</th></tr></thead><tbody valign="top"><tr><td align="right" rowspan="1" colspan="1">Age, mean &#177; SD</td><td align="right" rowspan="1" colspan="1">44.92 &#177; 12.06</td></tr><tr><td align="right" rowspan="1" colspan="1">Gender, n (%)</td><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Female</td><td align="right" rowspan="1" colspan="1">26 (5.7%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Male</td><td align="right" rowspan="1" colspan="1">426 (94.3%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;BMI, mean &#177; SD</td><td align="right" rowspan="1" colspan="1">23.52 &#177; 2.65</td></tr><tr><td align="right" rowspan="1" colspan="1">Nationality, n (%)</td><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Iran</td><td align="right" rowspan="1" colspan="1">429 (94.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Afghanistan</td><td align="right" rowspan="1" colspan="1">19 (4.2%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Arab</td><td align="right" rowspan="1" colspan="1">4 (0.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">City, n (%)</td><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Qom</td><td align="right" rowspan="1" colspan="1">160 (35.4%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Tehran</td><td align="right" rowspan="1" colspan="1">76 (16.8%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Mashhad</td><td align="right" rowspan="1" colspan="1">71 (15.7%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Esfahan</td><td align="right" rowspan="1" colspan="1">71 (15.7%)</td></tr><tr><td align="right" rowspan="1" colspan="1">&#8195;Kashan</td><td align="right" rowspan="1" colspan="1">74 (16.4%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Disease and medication history of patients referred to MMT centers. (n = 452).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">History</th><th align="left" rowspan="1" colspan="1">n = 452</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" rowspan="1">Underlying diseases, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Any disease</td><td align="left" rowspan="1" colspan="1">350 (77.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Heart</td><td align="left" rowspan="1" colspan="1">30 (6.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension</td><td align="left" rowspan="1" colspan="1">48 (10.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Kidney</td><td align="left" rowspan="1" colspan="1">13 (2.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes</td><td align="left" rowspan="1" colspan="1">9 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Rheumatoid</td><td align="left" rowspan="1" colspan="1">2 (0.4)</td></tr><tr><td colspan="2" align="left" rowspan="1">Drug abuse history, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;1 (year)</td><td align="left" rowspan="1" colspan="1">28 (6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1&#8211;5</td><td align="left" rowspan="1" colspan="1">141 (31.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;6&#8211;10</td><td align="left" rowspan="1" colspan="1">99 (21.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;11&#8211;15</td><td align="left" rowspan="1" colspan="1">64 (14.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;16&#8211;20</td><td align="left" rowspan="1" colspan="1">85 (18.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&gt;20</td><td align="left" rowspan="1" colspan="1">35 (7.7)</td></tr><tr><td colspan="2" align="left" rowspan="1">Drug abuse, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Opium</td><td align="left" rowspan="1" colspan="1">372 (82.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Marijuana</td><td align="left" rowspan="1" colspan="1">9 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Methamphetamines</td><td align="left" rowspan="1" colspan="1">16 (3.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Crack</td><td align="left" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Multidrug</td><td align="left" rowspan="1" colspan="1">54 (11.9)</td></tr><tr><td colspan="2" align="left" rowspan="1">MMT history, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;1&#8211;3 (year)</td><td align="left" rowspan="1" colspan="1">193 (42.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;4&#8211;6</td><td align="left" rowspan="1" colspan="1">164 (36.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;7&#8211;9</td><td align="left" rowspan="1" colspan="1">74 (16.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;10&#8211;12</td><td align="left" rowspan="1" colspan="1">18 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;13&#8211;15</td><td align="left" rowspan="1" colspan="1">3 (0.7)</td></tr><tr><td colspan="2" align="left" rowspan="1">MMT drug, n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Opium</td><td align="left" rowspan="1" colspan="1">28 (6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Methadone</td><td align="left" rowspan="1" colspan="1">340 (75.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Buprenorphine</td><td align="left" rowspan="1" colspan="1">84 (18.6)</td></tr></tbody></table></table-wrap><p>The prevalence of COVID-19 symptoms in the second trimester of the study period (second follow-up) was higher among patients than in the first trimester (first follow-up) (<xref rid="T3" ref-type="table">Table 3</xref>). 80.6% and 74.1% of patients in first and second follow-up respectively, have not shown any symptoms (<xref rid="F2" ref-type="fig">Figure 2</xref>). The results also have not shown any significant difference in the severity of COVID-19 symptoms in different nationalities (first follow-up: <italic toggle="yes">p</italic> = 0.241; second follow-up: <italic toggle="yes">p</italic> = 0.376), gender (first follow-up: <italic toggle="yes">p</italic> = 0.972; second follow-up: <italic toggle="yes">p</italic> = 0.503), and treatment groups (first follow-up: <italic toggle="yes">p</italic> = 0.565; second follow-up: <italic toggle="yes">p</italic> = 0.444). Furthermore, no statistically significant association was observed between the history of drug abuse (first follow-up: <italic toggle="yes">p</italic> = 0.671; second follow-up: <italic toggle="yes">p</italic> = 0.182) and smoking (first follow-up: <italic toggle="yes">p</italic> = 0.623; second follow-up: <italic toggle="yes">p</italic> = 0.788) with the occurrence of symptoms. Only the prevalence of symptoms in the mentioned cities (first and second follow-up: <italic toggle="yes">p</italic> &lt; 0.001) and individuals with a history of underlying disease (first follow-up: <italic toggle="yes">p</italic> = 0.020; second follow-up: <italic toggle="yes">p</italic> = 0.043) were significantly different (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Clinical symptoms of patients referred to MMT centers. (n = 452).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Symptom</th><th align="left" rowspan="1" colspan="1">First follow-up</th><th align="left" rowspan="1" colspan="1">Second follow-up</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">364 (80.5)</td><td align="left" rowspan="1" colspan="1">335 (74.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cough, n (%)</td><td align="left" rowspan="1" colspan="1">23 (5.1)</td><td align="left" rowspan="1" colspan="1">37 (8.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever, n (%)</td><td align="left" rowspan="1" colspan="1">37 (8.2)</td><td align="left" rowspan="1" colspan="1">54 (11.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Myalgia, n (%)</td><td align="left" rowspan="1" colspan="1">34 (7.5)</td><td align="left" rowspan="1" colspan="1">53 (11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache, n (%)</td><td align="left" rowspan="1" colspan="1">39 (8.6)</td><td align="left" rowspan="1" colspan="1">53 (11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea, n (%)</td><td align="left" rowspan="1" colspan="1">23 (5.1)</td><td align="left" rowspan="1" colspan="1">42 (9.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea, n (%)</td><td align="left" rowspan="1" colspan="1">46 (10.2)</td><td align="left" rowspan="1" colspan="1">59 (13.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Loss of taste or smell, n (%)</td><td align="left" rowspan="1" colspan="1">26 (5.8)</td><td align="left" rowspan="1" colspan="1">49 (10.8)</td></tr></tbody></table></table-wrap><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Symptoms severity of patients referred to MMT centers at first and second follow-ups (n = 452); None, no symptom; Mild, one to two symptoms; Moderate, three symptoms; Severe, &#8805;4 symptoms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1105176-g002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Percentage of patients with severe COVID-19 (&#8805;4 symptoms) referred to MMT centers in the first and second follow-ups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1105176-g003.jpg"/></fig><p>During a 6-month study duration, 4 (0.88%) death were recorded among the 452 patients referred to MMT clinics. 12 (2.65%) patients were hospitalized for COVID, as well.</p></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><p>The debate on whether opioids could help to improve or prevent COVID-19 has arisen since the beginning of the outbreak of this pandemic. So, we decided to investigate the incidence of symptoms and hospitalization in patients undergoing opioid maintenance therapy. Opioid agonist medications, including methadone, buprenorphine, and opium, have been administered at a specialized addiction clinic in Iran to treat opioid use disorder (OUD). In this study, the incidence rate of clinical symptom due to COVID-9 in patients undergoing different maintenance therapy treatment have not shown any significant difference. Also, other factors such as sex, body mass index (BMI), race, smoking, and abuse history have not been associated with COVID-19 symptom occurrence.</p><p>Salimi et al. have shown that opioid receptor signaling can control the severity of respiratory disease by influencing syncytial virus replication. Other clinical and experimental studies also have indicated that opioid receptor signaling has a potentially beneficial role in the outcome of respiratory viral disease. In influenza and respiratory syncytial viruses (RSVs), opioids reduce the rate and severity of infection through anti-inflammatory and immunomodulatory functions (<xref rid="B29" ref-type="bibr">Salimi et al., 2013</xref>).</p><p>
<xref rid="B4" ref-type="bibr">Cismaru et al. (2021)</xref> previously reported that none of the opioid medications are superior to others in treating dyspnea. So, oxycodone, hydromorphone fentanyl dihydrocodeine, diamorphine, and oral or parenteral morphine can be used for this purpose.</p><p>Matsunaga M showed genetic differences are effective in expressing opioid receptors in immune function and secretion of proinflammatory factors IL6, IL8, and TNF-&#945; (<xref rid="B23" ref-type="bibr">Matsunaga et al., 2009</xref>).</p><p>
<xref rid="B21" ref-type="bibr">Maher et al. (2019)</xref> showed that opioid peptides have suppressive effects on the cytotoxic function of natural killer cells. Stimulating opioid receptors reduce mucus secretion in the respiratory system (<xref rid="B17" ref-type="bibr">Krajnik et al., 2014</xref>). They also play a significant role in immune system activity, including antibody production, lymphocyte proliferation, and modulation of cytokine production. Furthermore, Opioids suppress IL6 signaling pathways (<xref rid="B7" ref-type="bibr">Eisenstein, 2019</xref>).</p><p>
<xref rid="B6" ref-type="bibr">De Wilde et al. (2014)</xref> demonstrated loperamide as an opioid receptor agonist inhibits MERS-CoV, SARS coronavirus, and human coronavirus 229E replication.</p><p>On the other hand, <xref rid="B8" ref-type="bibr">El-Hage et al. (2011)</xref> reported that morphine is involved in the pathogenesis of hepatitis C virus-infected hepatocytes by impairing cytokine expression and altering the production of reactive oxygen species and nitric oxide. Furthermore, morphine enhances the severity of primary herpes virus infection (<xref rid="B24" ref-type="bibr">Mojadadi et al., 2009</xref>) and secondary bacterial pneumonia lung infection (<xref rid="B33" ref-type="bibr">Wang J. et al., 2005</xref>).</p><p>Since using opioids is known to have immunosuppressive effects, infection due to the 2019 novel coronavirus disease has been one of the major concerns in people using opioids during the pandemic. It is reported that there is a considerable association between ICU admission and using opioids in patients with COVID-19. It is also worth mentioning that compared to non-users, higher mortality is recorded among opioid users (<xref rid="B1" ref-type="bibr">Ao et al., 2022</xref>).</p><p>In a study regarding long-term opioid therapy in patients, it was stated that due to compromised respiratory and immune function, susceptibility to COVID-19 infection increases. It was also reported that the risk of mortality and morbidity increases in these patients (<xref rid="B32" ref-type="bibr">Tuan et al., 2021</xref>).</p><p>Therefore, all aspects should be weighed before using opioids to treat an inflammatory viral respiratory infection, and caution is required.</p><p>Numerous studies have demonstrated the anti-inflammatory and immunomodulatory effects of opioids and the presence of opioid peptides in immune cells to reduce inflammatory hyperalgesia (<xref rid="B20" ref-type="bibr">Machelska and Celik, 2020</xref>).</p><p>It has also been shown that immune factors are significantly reduced after exposure of consumers (drug users, healthy human subjects, and animal models) to opioid compounds (<xref rid="B27" ref-type="bibr">Roy et al., 2011</xref>). However, this immunosuppression efficacy cannot be generalized to all opioid compounds. Just morphine, fentanyl, and remifentanil have immunosuppressive effects, and other compounds such as tramadol and buprenorphine have neutral impacts on the immunity system. Animal studies have shown a suppressive effect of methadone, but clinical studies as maintenance therapy in heroin-addicted patients have indicated immune function restoration (<xref rid="B11" ref-type="bibr">Franchi et al., 2019</xref>).</p><p>
<xref rid="B12" ref-type="bibr">Ghafari et al. (2021)</xref> have found that Iran has a significantly high death rate in the spring and summer of 2020 due to the uncontrolled transmission of the virus.</p><p>Concerning, the high estimated level of exposure in Qom (57% exposed) based on previous data compared to other cities in this study, it is expected to have a higher mortality rate during the time of the crisis, which results do not show such a finding compared to Tehran with 22% population-level exposure to the virus (<xref rid="B12" ref-type="bibr">Ghafari et al., 2021</xref>). However, Small sample sizes pose challenges to any statistical analyses.</p><p>Many studies have demonstrated that older age, male sex, race (mainly Black, Hispanic, and South Asian), and underlying comorbidities have been associated with disease severity or death of COVID-19 patients (<xref rid="B2" ref-type="bibr">Attaway et al., 2021</xref>)<italic toggle="yes">.</italic> Our results also have shown that the severity of symptoms in people with the underlying diseases was significantly different from others. But sex and race did not have significant effects on the severity of COVID-19 symptoms in MMT patients.</p><p>The limitation of this study was the lack of a control group (do not consume any opioid compounds) to investigate the relationship between opioid use and COVID-19 outcomes. Therefore, large-scale studies in different ethnic and geographical groups are needed to evaluate the relationship between opioids and survival in COVID-19 and clarify the effects of opioids on the clinical prognosis of COVID-19 patients. Therefore, it is suggested that studies be conducted to investigate how opioid use may impact immunity in the lungs and alter viral replication and virus-mediated pathology in COVID-19. We also did not have complete information on the mortality rate of patients in light centers in the same period of previous years to estimate excess mortality associated with COVID-19. Also, we only had access to the data of a limited number of MMT centers related to COVID-19 in different parts of Iran. Another limitation of this study was the lack of accompanying patients to complete laboratory tests and chest CTs. Therefore, the complete laboratory data was not available to the researchers for analysis.</p><p>Finally, more research needs to be done to determine if opioid administration can be helpful in viral diseases, specially COVID-19, or not. Furthermore, opioid addiction and misuse should be considered, and the potential benefits and harms during treatment should be weighed.</p></sec><sec sec-type="conclusion" id="s6"><title>Conclusion</title><p>Considering that the anti-inflammatory and immunomodulatory effects of opioids have been demonstrated in numerous studies, we decided to investigate the incidence of symptoms and hospitalization in patients undergoing opioid maintenance therapy. Our results have indicated that the severity of symptoms in people with the underlying disease was significantly higher than in other patients who did not have any underlying disease. But sex, race, treatment groups, and abuse history did not have any significant association with the severity of COVID-19 symptoms in methadone maintenance treatment (MMT) patients.</p></sec></body><back><ack><p>We thank patients and clinicians of MMT clinics who participated in this research. We particularly acknowledge the assistance of Dr. Mohammad Abdekhoda and Dr. Narges Gholami; managers of substance abuse treatment center.</p></ack><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p></sec><sec id="s8"><title>Ethics statement</title><p>The studies involving human participants were reviewed and approved by Ethics Committee of Qom University of Medical Sciences in Qom, Iran IR.MUQ.-REC.1394.73. The patients/participants provided their written informed consent to participate in this study.</p></sec><sec id="s9"><title>Author contributions</title><p>Study concept and design: SK. Acquisition of data: SK, ME, and MY. Drafting of the manuscript: SK, ME, and MY. Critical revision of the manuscript for important intellectual content: SH and JT. Study supervision: SH.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Opioid usage and COVID-19 prognosis: A systematic review and meta-analysis</article-title>. <source>Am. J. Emerg. Med.</source><volume>56</volume>, <fpage>51</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2022.03.048</pub-id><pub-id pub-id-type="pmid">35366438</pub-id><pub-id pub-id-type="pmcid">PMC8957893</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attaway</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Scheraga</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Bhimraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biehl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatipo&#287;lu</surname><given-names>U. J. b.</given-names></name></person-group> (<year>2021</year>). <article-title>Severe Covid-19 pneumonia: Pathogenesis and clinical management</article-title>. <source>BMJ</source><volume>372</volume>, <fpage>n436</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.n436</pub-id><pub-id pub-id-type="pmid">33692022</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: A descriptive study</article-title>. <source>Lancet</source><volume>395</volume> (<issue>10223</issue>), <fpage>507</fpage>&#8211;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id><pub-id pub-id-type="pmcid">PMC7135076</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cismaru</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cismaru</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Nabavi</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Ghanei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burz</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Nabavi</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19</article-title>. <source>J. Cell. Mol. Med.</source><volume>25</volume> (<issue>1</issue>), <fpage>591</fpage>&#8211;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15927</pub-id><pub-id pub-id-type="pmid">33211389</pub-id><pub-id pub-id-type="pmcid">PMC7753383</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Landt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Euro Surveill.</source><volume>25</volume> (<issue>3</issue>), <fpage>2000045</fpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.Es.2020.25.3.2000045</pub-id><pub-id pub-id-type="pmid">31992387</pub-id><pub-id pub-id-type="pmcid">PMC6988269</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Wilde</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Jochmans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Van Nieuwkoop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>58</volume> (<issue>8</issue>), <fpage>4875</fpage>&#8211;<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id><pub-id pub-id-type="pmid">24841269</pub-id><pub-id pub-id-type="pmcid">PMC4136071</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenstein</surname><given-names>T. K. J.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of opioid receptors in immune system function</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>2904</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02904</pub-id><pub-id pub-id-type="pmid">31921165</pub-id><pub-id pub-id-type="pmcid">PMC6934131</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dever</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F. J. J.</given-names></name></person-group> (<year>2011</year>). <article-title>HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: Increased pathogenesis coincides with uncoordinated host defenses</article-title>. <source>J. Virol.</source><volume>85</volume> (<issue>22</issue>), <fpage>11601</fpage>&#8211;<lpage>11614</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.05239-11</pub-id><pub-id pub-id-type="pmid">21900165</pub-id><pub-id pub-id-type="pmcid">PMC3209310</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>D.</given-names></name><name name-style="western"><surname>H Lazarus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y. J. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Current research on opioid receptor function</article-title>. <source>Curr. Drug Targets</source><volume>13</volume> (<issue>2</issue>), <fpage>230</fpage>&#8211;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.2174/138945012799201612</pub-id><pub-id pub-id-type="pmid">22204322</pub-id><pub-id pub-id-type="pmcid">PMC3371376</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Happel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression</article-title>. <source>Cell. Immunol.</source><volume>252</volume> (<issue>1-2</issue>), <fpage>146</fpage>&#8211;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2007.09.008</pub-id><pub-id pub-id-type="pmid">18279847</pub-id><pub-id pub-id-type="pmcid">PMC2538679</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moschetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amodeo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sacerdote</surname><given-names>P. J. F.</given-names></name></person-group> (<year>2019</year>). <article-title>Do all opioid drugs share the same immunomodulatory properties? A review from animal and human studies</article-title>. <source>Front. Immunol.</source><volume>10</volume>, <fpage>2914</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02914</pub-id><pub-id pub-id-type="pmid">31921173</pub-id><pub-id pub-id-type="pmcid">PMC6920107</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghafari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kadivar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katzourakis</surname><given-names>A. J. I. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Excess deaths associated with the Iranian COVID-19 epidemic: A province-level analysis</article-title>. <source>Int. J. Infect. Dis.</source><volume>107</volume>, <fpage>101</fpage>&#8211;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2021.04.015</pub-id><pub-id pub-id-type="pmid">33862214</pub-id><pub-id pub-id-type="pmcid">PMC8208896</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grass</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Toole</surname><given-names>B. P.</given-names></name></person-group> (<year>2015</year>). <article-title>How, with whom and when: An overview of cd147-mediated regulatory networks influencing matrix metalloproteinase activity</article-title>. <source>Biosci. Rep.</source><volume>36</volume> (<issue>1</issue>), <fpage>e00283</fpage>. <pub-id pub-id-type="doi">10.1042/bsr20150256</pub-id><pub-id pub-id-type="pmid">26604323</pub-id><pub-id pub-id-type="pmcid">PMC4718507</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source><volume>395</volume> (<issue>10223</issue>), <fpage>497</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>Look</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pewe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Netland</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia</article-title>. <source>J. Virol.</source><volume>79</volume> (<issue>23</issue>), <fpage>14614</fpage>&#8211;<lpage>14621</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.79.23.14614-14621.2005</pub-id><pub-id pub-id-type="pmid">16282461</pub-id><pub-id pub-id-type="pmcid">PMC1287568</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ratts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gallogly</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: A review of the phases of illness and therapeutic agents</article-title>. <source>Virol. J.</source><volume>17</volume> (<issue>1</issue>), <fpage>154</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-020-01415-w</pub-id><pub-id pub-id-type="pmid">33059711</pub-id><pub-id pub-id-type="pmcid">PMC7558250</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krajnik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jassem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sobanski</surname><given-names>P. J. C. O.</given-names></name><name name-style="western"><surname>Care</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Opioid receptor bronchial tree: Current science</article-title>. <source>Curr. Opin. Support. Palliat. Care</source><volume>8</volume> (<issue>3</issue>), <fpage>191</fpage>&#8211;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1097/SPC.0000000000000072</pub-id><pub-id pub-id-type="pmid">25010531</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechien</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Chiesa-Estomba</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Hans</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Jouffe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saussez</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Loss of smell and taste in 2013 European patients with mild to moderate COVID-19</article-title>. <source>Ann. Intern Med.</source><volume>173</volume> (<issue>8</issue>), <fpage>672</fpage>&#8211;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.7326/m20-2428</pub-id><pub-id pub-id-type="pmid">32449883</pub-id><pub-id pub-id-type="pmcid">PMC7505100</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature</source><volume>426</volume> (<issue>6965</issue>), <fpage>450</fpage>&#8211;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machelska</surname><given-names>H.</given-names></name><name name-style="western"><surname>Celik</surname><given-names>M. &#214;. J. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Opioid receptors in immune and glial cells&#8212;Implications for pain control</article-title>. <source>Front. Immunol.</source><volume>11</volume>, <fpage>300</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00300</pub-id><pub-id pub-id-type="pmid">32194554</pub-id><pub-id pub-id-type="pmcid">PMC7064637</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maher</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>N. M. J. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Suppression of human natural killer cells by different classes of opioids</article-title>. <source>Anesth. Analg.</source><volume>128</volume> (<issue>5</issue>), <fpage>1013</fpage>&#8211;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0000000000004058</pub-id><pub-id pub-id-type="pmid">30801358</pub-id><pub-id pub-id-type="pmcid">PMC6726115</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahler</surname><given-names>D. A. J. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Opioids for refractory dyspnea</article-title>. <source>Opioids Refract. dyspnea</source><volume>7</volume> (<issue>2</issue>), <fpage>123</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1586/ers.13.5</pub-id><pub-id pub-id-type="pmid">23547989</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsunaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Isowa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kasugai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Association of polymorphism in the human &#956;-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception</article-title>. <source>Brain Behav. Immun.</source><volume>23</volume> (<issue>7</issue>), <fpage>931</fpage>&#8211;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2009.03.007</pub-id><pub-id pub-id-type="pmid">19341791</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mojadadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khansarinejad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soleimanjahi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bamdad</surname><given-names>T. J. C.</given-names></name><name name-style="western"><surname>immunology</surname><given-names>m.</given-names></name></person-group> (<year>2009</year>). <article-title>Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice</article-title>. <source>BALB/c mice</source><volume>6</volume> (<issue>2</issue>), <fpage>111</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2009.15</pub-id><pub-id pub-id-type="pmcid">PMC4002647</pub-id><pub-id pub-id-type="pmid">19403060</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouri-Vaskeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kalami</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Soroureddin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Varshochi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ansarin</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial</article-title>. <source>Int. J. Clin. Pract.</source><volume>75</volume> (<issue>6</issue>), <fpage>e14124</fpage>. <pub-id pub-id-type="doi">10.1111/ijcp.14124</pub-id><pub-id pub-id-type="pmid">33650197</pub-id><pub-id pub-id-type="pmcid">PMC7995089</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pourkarim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pourtaghi-Anvarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Entezari-Maleki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asvadi-Kermani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nouri-Vaskeh</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview</article-title>. <source>Pharmacol. Res. Perspect.</source><volume>9</volume> (<issue>1</issue>), <fpage>e00705</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.705</pub-id><pub-id pub-id-type="pmid">33421347</pub-id><pub-id pub-id-type="pmcid">PMC7796804</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ninkovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charboneau</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Opioid drug abuse and modulation of immune function: Consequences in the susceptibility to opportunistic infections</article-title>. <source>J. Neuroimmune Pharmacol.</source><volume>6</volume> (<issue>4</issue>), <fpage>442</fpage>&#8211;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9292-5</pub-id><pub-id pub-id-type="pmid">21789507</pub-id><pub-id pub-id-type="pmcid">PMC3601186</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campion</surname><given-names>E. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Medical journals and the 2019-nCoV outbreak</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume> (<issue>9</issue>), <fpage>866</fpage>. <pub-id pub-id-type="doi">10.1056/NEJMe2001329</pub-id><pub-id pub-id-type="pmid">31986242</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hennus</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Mokhtari-Azad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shokri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hodemaekers</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Opioid receptors control viral replication in the airways</article-title>. <source>Crit. Care Med.</source><volume>41</volume> (<issue>1</issue>), <fpage>205</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e31826767a8</pub-id><pub-id pub-id-type="pmid">23222260</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senefeld</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Franchini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mengoli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cruciani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>E. K.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>COVID-19 convalescent plasma for the treatment of immunocompromised patients: A systematic review and meta-analysis</article-title>. <source>JAMA Netw. Open</source><volume>6</volume> (<issue>1</issue>), <fpage>e2250647</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.50647</pub-id><pub-id pub-id-type="pmid">36633846</pub-id><pub-id pub-id-type="pmcid">PMC9857047</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahamtan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tavakoli-Yaraki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mokhtari-Azad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teymoori-Rad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bont</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shokri</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Opioids and viral infections: A double-edged sword</article-title>. <source>Front. Microbiol.</source><volume>7</volume>, <fpage>970</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2016.00970</pub-id><pub-id pub-id-type="pmid">27446011</pub-id><pub-id pub-id-type="pmcid">PMC4916179</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuan</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Spotts</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zgierska</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Lennon</surname><given-names>R. P.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 outcomes among adult patients treated with long-term opioid therapy for chronic non-cancer pain in the USA: A retrospective cohort study</article-title>. <source>BMJ Open</source><volume>11</volume> (<issue>11</issue>), <fpage>e056436</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2021-056436</pub-id><pub-id pub-id-type="pmcid">PMC8628115</pub-id><pub-id pub-id-type="pmid">34836910</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barke</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Charboneau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S. J. T. J.</given-names></name></person-group> (<year>2005a</year>). <article-title>Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection</article-title>. <source>J. Immunol.</source><volume>174</volume> (<issue>1</issue>), <fpage>426</fpage>&#8211;<lpage>434</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.174.1.426</pub-id><pub-id pub-id-type="pmid">15611267</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S. J. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Historical review: Opiate addiction and opioid receptors</article-title>. <source>Cell Transpl.</source><volume>28</volume> (<issue>3</issue>), <fpage>233</fpage>&#8211;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1177/0963689718811060</pub-id><pub-id pub-id-type="pmcid">PMC6425114</pub-id><pub-id pub-id-type="pmid">30419763</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W. Z. J. J.</given-names></name></person-group> (<year>2005b</year>). <article-title>Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells</article-title>. <source>J. Leukoc. Biol.</source><volume>78</volume> (<issue>3</issue>), <fpage>772</fpage>&#8211;<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0305167</pub-id><pub-id pub-id-type="pmid">16000393</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: Immunopathogenesis and immunotherapeutics</article-title>. <source>Signal Transduct. Target Ther.</source><volume>5</volume> (<issue>1</issue>), <fpage>128</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00243-2</pub-id><pub-id pub-id-type="pmid">32712629</pub-id><pub-id pub-id-type="pmcid">PMC7381863</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>